The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
HIV-associated cryptococcal meningitis
Abstract
Introduction While the incidence of cryptococccal meningitis in the developed world has declined with widespread, early antiretroviral therapy (ART), cryptococcal disease remains a major opportunistic infection and leading cause of mortality in patients infected with HIV in much of the developing world. Most HIV-related cases are caused by Cryptococcus neoformans var. grubii (serotype A), while var. neoformans (serotype D) is responsible for a proportion, especially in Europe, and there are a small number of Cryptococcus gatti infections (formerly C. neoformans serotypes B and C) [1,2]. The last includes a small number of cases in HIV-infected individuals forming part of an unprecedented outbreak of C. gattii infections, predominantly in apparently immunocompetent patients, on Vancouver Island, Canada [3,4]. C. neoformans is distributed worldwide. An ubiquitous environmental saphrophyte, it is found in soil contaminated with pigeon droppings and has also been isolated from the heartwood of several tree species in South America [5] and India [6], and from the homes of African HIV-seropositive patients [7,8]. Exposure may be common [9], although the exact circumstances are usually unclear. Inhalation of small, thinly encapsulated yeasts, or basidiospores [10], may lead to an initial pulmonary infection, which, depending on host immune response and the number and virulence of the organisms, is cleared, contained within granulomata as a latent infection or disseminates. The minority in whom disease disseminates typically have defects in T cell function, through malignancy, immunosuppressive medication, autoimmune disease or sarcoidosis [11,12] or HIV infection, indicating the role of T cell-mediated immunity in host defence. In HIV-seropositive patients, most episodes of cryptococcal meningitis probably represent reactivation of latent infection, which may have been acquired many years earlier. There is compelling evidence for latent infection in a rat model [13] and humans [14]. Dromer and colleagues [15] typed C. neoformans isolates from HIV-seropositive patients diagnosed with cryptococcosis in France, some of whom were from Africa but had lived in France for a median of over 9 years. There was a significant clustering of isolates from African compared with European patients, suggesting that the patients had acquired their isolates long before the development of clinical disease. A proportion of HIV-related cases, however, may result from dissemination of new or primary infection [16], as has been observed in the recent outbreak of C. gattii infection in British Columbia [17]. HIV-associated cryptococcal meningitis usually presents as a subacute meningo-encephalitis in profoundly immunosuppressed patients (CD4 cell counts < 100 cells/μl), with malaise, headache, fever and, later, visual disturbance and altered mental status. Signs, if present, may include meningism, papilloedema, cranial nerve palsies [particularly sixth nerve palsies reflective of raised pressure in cerebrospinal fluid (CSF)] and reduced conscious level. The diagnosis is usually straightforward. The high organism load in this setting means the sensitivity of India ink staining of CSF is high. Those who have a negative result with India ink can be diagnosed by highly sensitive and specific cryptococcal antigen testing of CSF, or serum if CSF cannot be obtained [18]. Lumbar puncture often reveals markedly elevated opening pressures, an important complicating factor, with only modestly elevated or normal white cell counts (usually lymphocytes), elevated protein and low or normal glucose. High organism burden at baseline (indicated by quantitative CSF culture or CSF antigen titre) and abnormal mental status are the most important predictors of death [19,20], while high opening pressures and a poor inflammatory response in the CSF have also been associated with poor outcome [19,21,22]. Autopsy series reveal the lack of a protective granulomatous response in HIV-seropositive patients with cryptococcal meningitis. There is extensive involvement of brain parenchyma in addition to meningitis and higher organism burdens (which are predominantly extracellular) compared with the infection in HIV-seronegative individuals [23–25]. The remainder of this review will focus on the current epidemiology and management of HIV-associated cryptococcal meningitis, with some emphasis on the developing world where the burden of disease is highest. In addition to antifungal therapy, the important complications of elevated CSF pressure and immune reconstitution inflammatory syndrome (IRIS) and future approaches to prevention and therapy are discussed. Epidemiology Increasing numbers of cases of cryptococcal meningitis were reported in young adults in the former Zaire throughout the 1960s, possibly representing the first signs of the evolving HIV epidemic [26,27]. The late 1970s and early 1980s saw a sharp increase in the numbers of cases both in Kinshasa [28,29] and i
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Practice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Kaplan, J. E., Hanson, D., Dworkin, M. S., Frederick, T., Bertolli, J., Lindegren, M. L., Holmberg, S., & Jones, J. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313843 · Cited by 705
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
SHELBURNE, S. A., HAMILL, R. J., RODRIGUEZ-BARRADAS, M. C., GREENBERG, S. B., ATMAR, R. L., MUSHER, D. M., GATHE, J. C., VISNEGARWALA, F., & TRAUTNER, B. W. (2002) · Medicine · doi:10.1097/00005792-200205000-00005 · Cited by 654
Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K., Thompson, S. E., Sugar, A. M., Tuazon, C. U., Fisher, J. F., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260202 · Cited by 631
The mortality and pathology of HIV infection in a West African city
Lucas, S. B., Hounnou, A., Peacock, C., Beaumel, A., Djomand, G., NʼGbichi, J.-M., Yeboue, K., Hondé, M., Diomande, M., Giordano, C., et al. (1993) · AIDS · doi:10.1097/00002030-199312000-00005 · Cited by 562
Lawn, S. D., Bekker, L.-G., & Miller, R. F. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70140-7 · Cited by 545
Graybill, J. R., Sobel, J., Saag, M., van der Horst, C., Powderly, W., Cloud, G., Riser, L., Hamill, R., Dismukes, W., & NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups (2000) · Clinical Infectious Diseases · doi:10.1086/313603 · Cited by 486
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
Brouwer, A. E., Rajanuwong, A., Chierakul, W., Griffin, G. E., Larsen, R. A., White, N. J., & Harrison, T. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16301-0 · Cited by 470
Self-citationChen, S., Sorrell, T., Nimmo, G., Speed, B., Currie, B., Ellis, D., Marriott, D., Pfeiffer, T., Parr, D., & Byth, K. (2000) · Clinical Infectious Diseases · doi:10.1086/313992 · Cited by 467
Mirza, S. A., Phelan, M., Rimland, D., Graviss, E., Hamill, R., Brandt, M. E., Gardner, T., Sattah, M., Ponce de Leon, G., Baughman, W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/368091 · Cited by 459
Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults
French, N., Gray, K., Watera, C., Nakiyingi, J., Lugada, E., Moore, M., Lalloo, D., Whitworth, J. A. G., & Gilks, C. F. (2002) · AIDS · doi:10.1097/00002030-200205030-00009 · Cited by 417
Serologic Evidence for Cryptococcus neoformans Infection in Early Childhood
Goldman, D. L., Khine, H., Abadi, J., Lindenberg, D. J., Pirofski, L.-A., Niang, R., & Casadevall, A. (2001) · Pediatrics · doi:10.1542/peds.107.5.e66 · Cited by 413
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Lawn, S. D., Myer, L., Orrell, C., Bekker, L.-G., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000194802.89540.e1 · Cited by 359
Larsen, R. A., Leal, M. A. E., & Chan, L. S. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-183 · Cited by 357
Ratnam, I., Chiu, C., Kandala, N. B., & Easterbrook, P. J. (2006) · Clinical Infectious Diseases · doi:10.1086/499356 · Cited by 355
Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261203 · Cited by 353
PROLONGED PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE
(1964) · The Lancet · doi:10.1016/s0140-6736(64)91522-3 · Cited by 340
Lortholary, O., Fontanet, A., Mémain, N., Martin, A., Sitbon, K., & Dromer, F. (2005) · AIDS · doi:10.1097/01.aids.0000174450.70874.30 · Cited by 324
Epidemiological Evidence for Dormant Cryptococcus neoformans Infection
Garcia-Hermoso, D., Janbon, G., & Dromer, F. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.10.3204-3209.1999 · Cited by 323
Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the alpha-mating type.
Wickes, B. L., Mayorga, M. E., Edman, U., & Edman, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7327 · Cited by 307
Shelburne, III, Darcourt, J., White, Jr., Greenberg, S. B., Hamill, R. J., Atmar, R. L., & Visnegarwala, F. (2005) · Clinical Infectious Diseases · doi:10.1086/428618 · Cited by 305
Bozzette, S. A., Larsen, R. A., Chiu, J., Leal, M. A. E., Jacobsen, J., Rothman, P., Robinson, P., Gilbert, G., McCutchan, J. A., Tilles, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102283240902 · Cited by 301
Leenders, A. C. A. P., Reiss, P., Portegies, P., Clezy, K., Hop, W. C. J., Hoy, J., Borleffs, J. C. C., Allworth, T., Kauffmann, R. H., Jones, P., et al. (1997) · AIDS · doi:10.1097/00002030-199712000-00010 · Cited by 289
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Hajjeh, R. A., Conn, L. A., Stephens, D. S., Baughman, W., Hamill, R., Graviss, E., Pappas, P. G., Thomas, C., Reingold, A., Rothrock, G., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/314606 · Cited by 275
Bicanic, T., Meintjes, G., Wood, R., Hayes, M., Rebe, K., Bekker, L.-G., & Harrison, T. (2007) · Clinical Infectious Diseases · doi:10.1086/518607 · Cited by 271
Self-citationLutsar, I., Roffey, S., & Troke, P. (2003) · Clinical Infectious Diseases · doi:10.1086/377131 · Cited by 262
Activity of posaconazole in the treatment of central nervous system fungal infections
Pitisuttithum, P., Negroni, R., Graybill, J. R., Bustamante, B., Pappas, P., Chapman, S., Hare, R. S., & Hardalo, C. J. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki288 · Cited by 251
Saag, M. S., Cloud, G. A., Graybill, J. R., Sobel, J. D., Tuazon, C. U., Johnson, P. C., Fessel, W. J., Moskovitz, B. L., Wiesinger, B., Cosmatos, D., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515110 · Cited by 244
(2003) · PubMed · Cited by 240
Review of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan Africa
Holmes, C. B., Losina, E., Walensky, R. P., Yazdanpanah, Y., & Freedberg, K. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367655 · Cited by 237
Larsen, R. A., Pappas, P. G., Perfect, J., Aberg, J. A., Casadevall, A., Cloud, G. A., James, R., Filler, S., & Dismukes, W. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.952-958.2005 · Cited by 236
Pfaller, M. A., Messer, S. A., Boyken, L., Hollis, R. J., Rice, C., Tendolkar, S., & Diekema, D. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.008 · Cited by 234
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., & Burnie, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2208-2216.2003 · Cited by 231
Natural History of Human Immunodeficiency Virus Disease in Southern India
Kumarasamy, N., Solomon, S., Flanigan, T. P., Hemalatha, R., Thyagarajan, S. P., & Mayer, K. H. (2003) · Clinical Infectious Diseases · doi:10.1086/344756 · Cited by 227
Lee, S. C., Dickson, D. W., & Casadevall, A. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90459-1 · Cited by 224
Hakim, J. G., Gangaidzo, I. T., Heyderman, R. S., Mielke, J., Mushangi, E., Taziwa, A., Robertson, V. J., Musvaire, P., & Mason, P. R. (2000) · AIDS · doi:10.1097/00002030-200007070-00013 · Cited by 224
Bicanic, T., Harrison, T., Niepieklo, A., Dyakopu, N., & Meintjes, G. (2006) · Clinical Infectious Diseases · doi:10.1086/507895 · Cited by 224
Self-citationACQUIRED IMMUNE DEFICIENCY SYNDROME IN BLACK AFRICANS
Clumeck, N., Mascart-Lemone, F., De Maubeuge, J., Brenez, D., & Marcelis, L. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91808-1 · Cited by 209
Immune reconstitution inflammatory syndrome
BRETON, G. (2009) · Tuberculosis · doi:10.1016/b978-1-4160-3988-4.00067-6 · Cited by 206
Denning, D. W., Armstrong, R. W., Lewis, B. H., & Stevens, D. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90126-i · Cited by 205
Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Doern, G. V., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2163-2167.2005 · Cited by 205
Fluconazole Combined with Flucytosine for Treatment of Cryptococcal Meningitis in Patients with AIDS
Larsen, R. A., Bozzette, S. A., Jones, B. E., Haghighat, D., Leal, M. A., Forthal, D., Bauer, M., Tilles, J. G., McCutchan, J. A., & Leedom, J. M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.4.741 · Cited by 203
Robertson, J., Meier, M., Wall, J., Ying, J., & Fichtenbaum, C. J. (2006) · Clinical Infectious Diseases · doi:10.1086/503903 · Cited by 203
Recombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal Meningitis
Pappas, P. G., Bustamante, B., Ticona, E., Hamill, R. J., Johnson, P. C., Reboli, A., Aberg, J., Hasbun, R., & Hsu, H. H. (2004) · The Journal of Infectious Diseases · doi:10.1086/420829 · Cited by 202
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy
Lortholary, O., Poizat, G., Zeller, V., Neuville, S., Boibieux, A., Alvarez, M., Dellamonica, P., Botterel, F., Dromer, F., & Chêne, G. (2006) · AIDS · doi:10.1097/01.aids.0000252060.80704.68 · Cited by 198
Mwaba, P., Mwansa, J., Chintu, C., Pobee, J., Scarborough, M., Portsmouth, S., & Zumla, A. (2001) · Postgraduate Medical Journal · doi:10.1136/pgmj.77.914.769 · Cited by 198
Possible primary ecological niche of Cryptococcus neoformans
Lazera, M. S., Cavalcanti, M. A. S., Londero, A. T., Trilles, L., Nishikawa, M. M., & Wanke, B. (2000) · Medical Mycology · doi:10.1080/714030957 · Cited by 197
Denning, D. W., Kibbler, C. C., & Barnes, R. A. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00580-2 · Cited by 194
Prevention of Amphotericin B—Induced Renal Impairment: A Review on the Use of Sodium Supplementation
Branch, R. A. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380110049010 · Cited by 194
Corbett, E. L., Churchyard, G. J., Charalambos, S., Samb, B., Moloi, V., Clayton, T. C., Grant, A. D., Murray, J., Hayes, R. J., & De Cock, K. M. (2002) · Clinical Infectious Diseases · doi:10.1086/339540 · Cited by 185
Jenny‐Avital, E. R., & Abadi, M. (2002) · Clinical Infectious Diseases · doi:10.1086/344467 · Cited by 185
Wüthrich, M., Filutowicz, H. I., Warner, T., Deepe, G. S., & Klein, B. S. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030109 · Cited by 180
Goldman, D. L., Lee, S. C., Mednick, A. J., Montella, L., & Casadevall, A. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.832-838.2000 · Cited by 177
Early Mycological Treatment Failure in AIDS‐Associated Cryptococcal Meningitis
Robinson, P. A., Bauer, M., Leal, M. A. E., Evans, S. G., Holtom, P. D., Diamond, D. M., Leedom, J. M., & Larsen, R. A. (1999) · Clinical Infectious Diseases · doi:10.1086/515074 · Cited by 160
Woods, M. L., MacGinley, R., Eisen, D. P., & Allworth, A. M. (1998) · AIDS · doi:10.1097/00002030-199812000-00011 · Cited by 150
Chariyalertsak, S., Sirisanthana, T., Saengwonloey, O., & Nelson, K. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319348 · Cited by 149
Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections
Anaissie, E. J., Kontoyiannis, D. P., Huls, C. E., Vartivarian, S. E., Karl, C., Prince, R. A., Bosso, J. A., & Bodey, G. P. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.2.599 · Cited by 147
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 146
IFN-γ at the Site of Infection Determines Rate of Clearance of Infection in Cryptococcal Meningitis
Siddiqui, A. A., Brouwer, A. E., Wuthiekanun, V., Jaffar, S. S., Shattock, R. J., Irving, D., Sheldon, J., Chierakul, W., Peacock, S. J., Day, N., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1746 · Cited by 146
Self-citationCatastrophic Visual Loss Due to Cryptococcus neoformans Meningitis
Rex, J. H., Larsen, R. A., Dismukes, W. E., Cloud, G. A., & Bennett, J. E. (1993) · Medicine · doi:10.1097/00005792-199307000-00001 · Cited by 139
Lawn, S. D., Bekker, L., Myer, L., Orrell, C., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000191232.16111.f9 · Cited by 130
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
Perfect, J. R., Cox, G. M., Dodge, R. K., & Schell, W. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1910 · Cited by 129
Mayanja‐Kizza, H., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K., Izumi, T., Ococi-Jungala, Augustine, K., Mugerwa, R. D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516372 · Cited by 128
Mussini, C., Pezzotti, P., Miró, J. M., Martínez, E., de Quirós, J. C. L. B., Cinque, P. M., Borghi, V., Bedini, A., Domingo, P., Cahn, P. E., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381261 · Cited by 128
Vibhagool, A., D, S. S. M., Mootsikapun, P., Chetchotisakd, P., Tansuphaswaswadikul, S., Bowonwatanuwong, C., & Ingsathit, A. (2003) · Clinical Infectious Diseases · doi:10.1086/374849 · Cited by 127
Newton, P. N., Thai, L. H., Tip, N. Q., Short, J. M., Chierakul, W., Rajanuwong, A., Pitisuttithum, P., Chasombat, S., Phonrat, B., Maek-a-nantawat, W., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/342299 · Cited by 122
Bacterial Meningitis in Malawian Adults: Pneumococcal Disease is Common, Severe, and Seasonal
Gordon, S. B., Walsh, A. L., Chaponda, M., Gordon, M. A., Soko, D., Mbvwinji, M., Molyneux, M. E., & Read, R. C. (2000) · Clinical Infectious Diseases · doi:10.1086/313910 · Cited by 120
Management of Elevated Intracranial Pressure in Patients With Cryptococcal Meningitis
Fessler, R. D., Sobel, J. D., Guyot, L. L., et al. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199802010-00006 · Cited by 119
Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., & Ghannoum, M. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.169 · Cited by 119
Cryptococcosis: a review of the brazilian experience for the disease
Pappalardo, M. C. S. M., & Melhem, M. D. S. C. (2003) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652003000600001 · Cited by 117
Cryptococcal Meningitis in Human Immunodeficiency Virus–Infected Patients in Harare, Zimbabwe
Heyderman, R. S., Gangaidzo, I. T., Hakim, J. G., Mielke, J., Taziwa, A., Musvaire, P., Robertson, V. J., & Mason, P. R. (1998) · Clinical Infectious Diseases · doi:10.1086/516298 · Cited by 114
Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology
Klepser, M. E., Malone, D., Lewis, R. E., Ernst, E. J., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1917-1920.2000 · Cited by 108
Treatment of Hydrocephalus Secondary to Cryptococcal Meningitis by Use of Shunting
Park, M. K., Hospenthal, D. R., & Bennett, J. E. (1999) · Clinical Infectious Diseases · doi:10.1086/515161 · Cited by 106
Roling, E. E., Klepser, M. E., Wasson, A., Lewis, R. E., Ernst, E. J., & Pfaller, M. A. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00361-9 · Cited by 100
Bacterial meningitis associated with lumbar drains: a retrospective cohort study
Coplin, W. M., Avellino, A. M., Kim, D. K., Winn, H. R., & Grady, M. S. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.468 · Cited by 99
Okongo, M. J. (1998) · International Journal of Epidemiology · doi:10.1093/ije/27.4.698 · Cited by 99
Emergence of Cryptococcus gattii in a Novel Environment Provides Clues to Its Incubation Period
MacDougall, L., & Fyfe, M. W. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1851-1852.2006 · Cited by 98
Andes, D. R., & van Ogtrop, M. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 96
Lee, S. C., Casadevall, A., & Dickson, D. W. (1996) · Europe PMC (PubMed Central) · Cited by 94
High-Dose Fluconazole Therapy for Cryptococcal Meningitis in Patients with AIDS
Menichetti, F., Fiorio, M., Tosti, A., Gatti, G., Pasticci, M. B., Miletich, F., Marroni, M., Bassetti, D., & Pauluzzi, S. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.838 · Cited by 94
Primary Complex of Cryptococcus and Pulmonary Lymph Nodes
Salyer, W. R., Salyer, D. C., & Baker, R. D. (1974) · The Journal of Infectious Diseases · doi:10.1093/infdis/130.1.74 · Cited by 91
Nooney, L., Matthews, R., & Burnie, J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.08.013 · Cited by 88
Morgan, J., McCarthy, K., Gould, S., Fan, K., Arthington, B. A., Iqbal, N. J., Stamey, K., Hajjeh, R. A., Brandt, M. E., & Gauteng Cryptococcal Surveillance Initiative Group (2006) · Clinical Infectious Diseases · doi:10.1086/507897 · Cited by 87
Békondi, C., Bernède‐Bauduin, C., Passone, N., Minssart, P., Kamalo, C., Mbolidi, D., & Germani, Y. (2006) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2005.07.004 · Cited by 85
Serum Cryptococcal Antigen in Patients with AIDS
Feldmesser, M., Harris, C., Reichberg, S. B., Khan, S. M., & Casadevall, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.4.827 · Cited by 85
Yeo, E.-J., Ryu, J., Cho, Y.-S., Chun, Y., Huang, E. L., Kim, M., & Park, J. (2005) · Blood · doi:10.1182/blood-2005-06-2564 · Cited by 84
Barchiesi, F., Arzeni, D., Fothergill, A. W., Francesco, L. F. D., Caselli, F., Rinaldi, M. G., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.226-229.2000 · Cited by 80
Effects of Voriconazole on Cryptococcus neoformans
van Duin, D., Cleare, W., Zaragoza, Ó., Casadevall, A., & Nosanchuk, J. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2014-2020.2004 · Cited by 79
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis
Allendoerfer, R., Marquis, A. J., Rinaldi, M. G., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.726 · Cited by 78
Successful Treatment of Cerebral Blastomycosis with Voriconazole
Bakleh, M., Aksamit, A. J., Tleyjeh, I. M., & Marshall, W. F. (2005) · Clinical Infectious Diseases · doi:10.1086/429319 · Cited by 76
Haubrich, R., Haghighat, D., Bozzette, S. A., Tilles, J. G., McCutchan, J. A., & California Collaborative Treatment Group (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.1.238 · Cited by 74
Nguyen, M. H., & Yu, C. Y. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.471 · Cited by 73
Macsween, K. F., Bicanic, T. A., Brouwer, A. E., Marsh, H. T., Macallan, D. C., & Harrison, T. S. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.02.010 · Cited by 68
Self-citationChetchotisakd, P., D, S. S. M., Thinkhamrop, B., Mootsikapun, P., & Boonyaprawit, P. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00201.x · Cited by 64
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis
Bicanic, T. A., Wood, R., Bekker, L., Darder, M., Meintjes, G., & Harrison, T. S. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70197-3 · Cited by 63
Self-citationSelik, R. M., Karon, J. M., & Ward, J. W. (1997) · The Journal of Infectious Diseases · doi:10.1086/514083 · Cited by 63
ACQUIRED IMMUNODEFICIENCY SYNDROME IN FRANCE
Brunet, J., Bouvet, É., Chaperon, J., Jc, G., Kernbaum, S., Klatzmann, D., Lachiver, D., Leibowitch, J., Mayaud, C. M., Picard, O., et al. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91985-2 · Cited by 63
Aberg, J. A., Price, R. W., Heeren, D. M., & Bredt, B. M. (2002) · The Journal of Infectious Diseases · doi:10.1086/339680 · Cited by 62
Cryptococcal Meningitis after Unusual Exposures to Birds
Fessel, W. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281816 · Cited by 62
Brouwer, A. E., van Kan, H. J. M., Johnson, E., Rajanuwong, A., Teparrukkul, P., Wuthiekanun, V., Chierakul, W., Day, N., & Harrison, T. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01188-06 · Cited by 62
Self-citationAntifungal interventions for the primary prevention of cryptococcal disease in adults with HIV
Chang, L. W., Phipps, W. T., Kennedy, G. E., & Rutherford, G. W. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004773.pub2 · Cited by 61
Swinne, D., Deppner, M., Laroche, R., Jj, F., & Kadende, P. (1989) · AIDS · doi:10.1097/00002030-198906000-00009 · Cited by 61
Bach, M. C., Tally, P. W., & Godofsky, E. W. (1997) · Neurosurgery · doi:10.1097/00006123-199712000-00008 · Cited by 60
Schaars, C., Meintjes, G., Morroni, C., Post, F. A., & Maartens, G. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-118 · Cited by 55
Mediastinitis Due to Cryptococcal Infection: A New Clinical Entity in the HAART Era
Trevenzoli, M., Cattelan, A. M., Rea, F., Sasset, L., Semisa, M., Lanzafame, M., Meneghetti, F., & Cadrobbi, P. (2002) · Journal of Infection · doi:10.1016/s0163-4453(02)91052-2 · Cited by 55
Cryptococcus gattiiRisk for Tourists Visiting Vancouver Island, Canada
Lindberg, J. Å., Hagen, F., Laursen, A. L., Stenderup, J., & Boekhout, T. (2007) · Emerging infectious diseases · doi:10.3201/eid1301.060945 · Cited by 54
Ding, J. C., Bauer, M., Diamond, D. M., Leal, M. A., Johnson, D. L., Williams, B. K., Thomas, A., Najvar, L. K., Graybill, J. R., & Larsen, R. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1589 · Cited by 53
Towards a vaccine forCryptococcus neoformans: principles and caveats
Datta, K., & Pirofski, L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00073.x · Cited by 51
Manfredi, R., Pieri, F., Pileri, S. A., & Chiodo, F. (2000) · Mycopathologia · doi:10.1023/a:1007156027134 · Cited by 49
Trends in Incidence of AIDS Illnesses in Australia From 1983 to 1994: The Australian AIDS Cohort
Dore, G. J., Hoy, J., Mallal, S. A., Li, Y., Mijch, A. M., French, M. A., Cooper, D. A., & Kaldor, J. M. (1997) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199709010-00006 · Cited by 46
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods☆
Lewis, R. E., Klepser, M. E., & Pfaller, M. A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00125-x · Cited by 44
Perfect, J. R., & Durack, D. T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.6.751 · Cited by 43
Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection
Serena, C., Pastor, F. J., Mariné, M., Rodríguez, M. M., & Guarro, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm123 · Cited by 42
Systematic Screening of Cryptococcal Antigenemia in HIV-Positive Adults in Uganda
Tassie, J.-M., Pepper, L. J., Fogg, C., Biraro, S., Mayanja, B., Andia, I., Paugam, A., Priotto, G., & Legros, D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200307010-00019 · Cited by 41
Sorvillo, F. J., Beall, G. N., Turner, P. A., Beer, V. L., Kovacs, A., & Kerndt, P. R. (1997) · AIDS · doi:10.1097/00002030-199705000-00016 · Cited by 39
Sun, H., Hung, C., & Chang, S. (2004) · Clinical Infectious Diseases · doi:10.1086/421272 · Cited by 39
Polysaccharide Antigen in Brain Tissue of AIDS Patients with Cryptococcal Meningitis
Lee, S. C., & Casadevall, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.1.194 · Cited by 39
Coenjaerts, F. E. J., van der Flier, M., Mwinzi, P. N. M., Brouwer, A. E., Scharringa, J., Chaka, W., Aarts, M., Rajanuwong, A., van de Vijver, D. A. M. C., Harrison, T. S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423849 · Cited by 35
Self-citationPosaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection
Barchiesi, F., Spreghini, E., Schimizzi, A. M., Maracci, M., Giannini, D., Carle, F., & Scalise, G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3312-3316.2004 · Cited by 34
OʼDoherty, N., & Illingworth, R. S. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91731-6 · Cited by 33
Kartalija, M., Kaye, K. S., Tureen, J. H., Liu, Q., Täuber, M. G., ELLIOTT, B. R., & Sande, M. A. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1216 · Cited by 32
Molez, J.-F. (1998) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1998.58.273 · Cited by 29
Hoffmann, S., Stenderup, J., & Mathiesen, L. R. (1991) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549109024296 · Cited by 26
Efficacy of voriconazole in experimental Cryptococcus neoformans infection
Mavrogiorgos, N. C., Zaragoza, Ó., Casadevall, A., & Nosanchuk, J. D. (2006) · Mycopathologia · doi:10.1007/s11046-006-0039-4 · Cited by 16
Cited by
Davis, M. J., Tsang, T. M., Qiu, Y., Dayrit, J. K., Freij, J. B., Huffnagle, G. B., & Olszewski, M. A. (2013) · mBio · doi:10.1128/mbio.00264-13 · Cited by 448
Meya, D. B., Manabe, Y. C., Castelnuovo, B., Cook, B. A., Elbireer, A. M., Kambugu, A., Kamya, M. R., Bohjanen, P. R., & Boulware, D. R. (2010) · Clinical Infectious Diseases · doi:10.1086/655143 · Cited by 296
Jarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290
Self-citationCryptococcal meningitis: epidemiology and therapeutic options
Sloan, D., & Parris, V. (2014) · Clinical Epidemiology · doi:10.2147/clep.s38850 · Cited by 277
Jarvis, J. N., Meintjes, G., Bicanic, T., Buffa, V., Hogan, L., Mo, S., Tomlinson, G., Kropf, P., Noursadeghi, M., & Harrison, T. S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004754 · Cited by 150
“Epidemiological evidence clearly points to the importance of adequate CD4 T-cell mediated immunity in the control of cryptococcal infection [27, 28], and experimental data suggest that the phenotype of the CD4 T-cell response to Cryptococcus neoformans influences the outcome of CM [9, 29].”
BackgroundSelf-citation
Metadata
- Authors
- Jarvis, J. N., & Harrison, T. S.
- Venue
- AIDS
- Published
- 2007-10
- Volume
- 21
- Issue
- 16
- Pages
- 2119-2129
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W1989335709
- Cited by
- 252
- References
- 131
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.